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Poly(I:C)-Treated Human Langerhans Cells Promote
the Differentiation of CD4þ T Cells Producing IFN-c
and IL-10
Laetitia Furio1, Hermine Billard1, Jenny Valladeau1,2, Josette Pe´guet-Navarro1,3 and
Odile Berthier-Vergnes1,3,4
Epidermal Langerhans cells (LCs) are the first dendritic cells to encounter skin pathogens. However, their
function has recently been challenged, especially in the initiation of T-cell responses to viral antigens. We have
previously reported that fresh immature human LCs express mRNA encoding TLR3. Here we analyze the
response of highly purified human LCs to poly(I:C), a synthetic mimetic of viral dsRNA recognized by TLR3. We
show that LCs exposed for 2 days to poly(I:C) under serum-free conditions up-regulated co-stimulatory
molecules, a process associated with increased allostimulatory capacity. Furthermore, poly(I:C) significantly
enhanced LC survival and induced them to produce CXCL10, IL-6, and IL-12 p40. Bioactive IL-12 p70, IL-1b, IL-15,
IL-18, and IL-23 were never detected, even after CD40 ligation. LC incubation in the presence of bafilomycin
completely reversed the effect of poly(I:C) on LC phenotypic activation and survival, indicating that endosomal
TLR3 is involved in this process. Most interestingly, we report here that poly(I:C)-treated LCs favored alloreactive
CD4þ T-cell differentiation toward a Th1 profile and concomitant differentiation of IL-10-producing CD4þ T
cells that might limit, at another time, the inflammatory response and subsequent tissue damage.
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INTRODUCTION
Dendritic cells (DCs) play an essential role in microbe
recognition by their expression of pattern-recognition recep-
tors, especially Toll-like receptors (TLRs) (Akira et al., 2001;
Janeway and Medzhitov, 2002). In humans, 11 TLRs have so
far been shown to discriminate various pathogen-specific
host responses, each recognizing a specific set of pathogen-
associated molecular patterns. In particular, TLR2 in associa-
tion with TLR1 and/or TLR6 interacts with lipoproteins and
peptidoglycans from Gram-positive bacteria, TLR3 binds
double-stranded RNA (dsRNA) either present in viral geno-
mes or generated during viral replication, TLR4 binds LPS
from Gram-negative bacteria, TLR5 binds flagellin, TLR7 and
TLR8 bind imidazoquinolines and viral single-stranded RNA,
and TLR9 binds unmethylated bacterial CpG-containing
oligonucleotides (CpG ODN).
Depending on their developmental stage and lineage, DCs
exhibit distinct TLR profiles that contribute to the decision
between tolerance and immunity (Kapsenberg, 2003). Ligand
binding of TLRs triggers a program of DC maturation
characterized by up-regulation of surface expression of
MHC and co-stimulatory molecules, CCR7 expression, and
secretion of numerous cytokines and chemokines. As a
consequence, DCs migrate from the periphery to T-cell areas
of draining lymph nodes. There, such mature DCs have the
unique capacity to activate naive T cells and induce their
proliferation and differentiation into pathogen-specific effec-
tor T cells. However, distinct TLR ligands can activate DCs
differently to elicit diverse signaling pathways and cytokine
profiles, which dictate the T-helper polarization toward Th1
(producing IL-2, IFN-g), Th2 (IL-4, IL-5, IL-13), or even
regulatory T cells (IL-10 and/or TGFb) (Kapsenberg, 2003).
Langerhans cells (LCs) are a unique DC subset, residing in
an immature state in the epidermal layer of skin and
expressing specific markers such as CD1a, E-cadherin, and
langerin. LCs were initially thought to serve as the first line of
defense against viral, bacterial, and fungal pathogens
invading the skin and to be the primary cells responsible
for the initiation of the antigen-specific T-cell immune
response. However, recent data using mouse models have
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provided evidence that epidermal LCs play a minor role, if
any, in the priming of T cells in response to skin pathogens
ranging from viruses (Allan et al., 2003; Itano et al., 2003;
Zhao et al., 2003) to parasites (Ritter et al., 2004; Iezzi et al.,
2006). Indeed, the primary function of LCs has been proposed
to be the transport of skin antigens to draining lymph nodes for
transfer to, and presentation by, lymph-node-resident DC
populations (Allan et al., 2006). In contrast, dermal or
submucosal DCs were shown to be very efficient in T cell
priming after viral cutaneous infection (Allan et al., 2003; Zhao
et al., 2003). As LC-deficient mice develop enhanced contact
hypersensitivity (Kaplan et al., 2005), LCs were even thought to
induce regulatory rather than effector T-cell responses.
In humans, the functional relevance of epidermal LCs is
largely unknown. We have shown that LCs freshly isolated
from human skin exhibit a TLR profile that enables them to
respond to dsRNA viruses and Gram-positive bacteria, but not
Gram-negative bacteria (Flacher et al., 2006). Indeed, quanti-
tative RT–PCR analysis showed that epidermal LCs express
TLR1, TLR2, TLR3, and TLR6 but not TLR4 and TLR9. Here, we
sought to further analyze the functional response of human
epidermal LCs to viral stimulus. To this end, we exposed highly
purified human immature LCs to poly(I:C), a synthetic dsRNA
analog often used to mimic viral infection. We show that
poly(I:C) increased the LC life span and allostimulatory ability.
Most interestingly, we report here that poly(I:C) promotes the
LC-induced Th1 response and concomitant differentiation of IL-
10-producing CD4þ T cells that might limit the inflammatory
response and subsequent tissue damage.
RESULTS
Poly(I:C) strongly activates human epidermal LCs
We first analyzed the effect of poly(I:C) on LC phenotypic
activation/maturation. To this end, highly purified LCs were
prepared from human epidermis. As described earlier (Berthier-
Vergnes et al., 2005), these cells exhibit a typical immature
phenotype: high levels of CD1a, langerin, and CCR6; very low
levels of CD40, CD54, and CD86; and no CD80 and CD83
(data not shown). These fresh LCs were then cultured in serum-
free medium supplemented or not with poly(I:C) (10mg/ml),
LPS (100ng ml1), CpG-ODN 2216 (10mg ml1), or CD40-
Lþ IFN-g. After a 2-day culture without any stimulus, human
LCs expressed a high level of HLA-DR and all the above-
mentioned co-stimulatory and maturation molecules (Figure 1).
Poly(I:C), but not CpG or LPS, clearly enhanced the expression
of most activation markers, especially CD40, CD80, and CD86.
Figure 1a illustrates a representative experiment and Figure 1b
summarizes the results from five donors. These effects were
observed at a very low poly(I:C) concentration (5mg ml1, not
shown). Not only was the intensity of these markers increased
but also the percentage of positive cells (Figure S1). These
results confirm that human epidermal LCs respond to poly(I:C),
but not CpG or LPS, by enhancing the surface expression of
activation markers.
Poly(I:C) enhances LC survival upon in vitro culture
As reported earlier (Ludewig et al., 1995; Berthier-Vergnes
et al., 2005), LCs undergo spontaneous apoptosis upon in vitro
culture. In our experiments, however, we observed that
poly(I:C) enhanced the viable cell yield at the end of the
culture, that is, the absolute number of viable LCs retrieved
after the 2-day culture, in relation to the absolute number of
purified LCs plated on day 0. Indeed, in eight experiments, the
viable LC yield at day 2 averaged 66.8±6.1 and 75.6±7.3%
in the presence of poly(I:C) at 10 and 50mg ml1, respectively,
whereas it was only 45.6±9.8% in the absence of poly(I:C).
As assessed by the Student t-test for paired values, the data
obtained in the presence or absence of poly(I:C) were
statistically different, for both concentrations (Po0.001).
Therefore, we tested whether poly(I:C) can protect LCs from
spontaneous apoptosis by annexin V-FITC and propidium
iodide (PI) staining. As shown in a representative experiment
(Figure 2a), the percentage of viable LCs averaged 55% at day
2 and fell to 13% at day 4 in the presence of medium alone,
while most of the LCs became necrotic. In contrast, poly(I:C)
reduced LC mortality throughout the incubation period
(Figure 2a). Interestingly, the effect was observed at the
lowest poly(I:C) concentration (5mg ml1). In four experi-
ments, 10mg ml1 of poly(I:C) consistently increased the
percentage of viable LCs after a 2-day culture (Figure 2b).
Poly(I:C) enhances human LC allostimulatory capacity
Expression of co-stimulatory molecules plays a key role in
T-cell activation. Therefore, we examined the efficiency of
poly(I:C)-activated LCs in activating allogeneic T-cell pro-
liferation. To this end, LCs were recovered after the 2-day
culture in the presence, or not, of poly(I:C), CpG, or LPS.
Graded numbers of viable LCs were then added to allogeneic
T cells in a mixed LC-lymphocyte reaction. As shown in
Figure 3, LC allostimulatory function was consistently
enhanced when the cells were exposed to poly(I:C) or
CD40 ligation. In contrast, CpG or LPS had no effect on the
LCs’ capacity to induce allogeneic T-cell proliferation. The
enhancing effect of poly(I:C) on LC allostimulatory function
has been confirmed in two additional experiments. Note,
however, that it was most evident when a low number of
stimulating LCs were added (Figure S2).
Poly(I:C) induces LCs to secrete high levels of CXCL-10, IL-6,
and IL-12 p40, but not IL-10, IL-12 p70, IL-1b, IL-15, IL-18,
or IL-23
Because the DC cytokine secretion profile plays a crucial role
in the regulation of the T-cell immune response, we next
measured the levels of a panel of cytokines and chemokines
in supernatants of highly purified LCs treated with the various
stimuli. As shown in Figure 4, LCs incubated for 2 days in
medium alone produce very low or undetectable levels of the
tested soluble factors. As expected, addition of either CpG or
LPS did not alter these results. In contrast, LC stimulation with
poly(I:C) induced a high production of CXCL10 and
substantial level of IL-12p40, as did stimulation by
CD40Lþ IFN-g. Moreover, only poly(I:C) stimulation trig-
gered significant IL-6 production by LCs. Of note, the IL-6,
IL-12p40, and CXCL10 could not be attributed to the few
contaminating keratinocytes. Indeed, pellets of Nycoprep
(which mainly consisted of keratinocytes) treated with
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poly(I:C) did not produce significant levels of these cytokines
(not shown).
Interestingly, we failed to detect significant LC production
of IL-12 p70 in the presence of any stimuli (Figure 4), nor did
we detect IL-1b, IL-15, IL-18, or IL-23 (not shown). Moreover,
it is noteworthy that IL-10 and TNF-a levels were very low
under any condition.
TLR3 is involved in the LC response to poly(I:C)
Recent work has shown that poly(I:C) interacts with TLR3 in
endosomes, as bafilomycin, an inhibitor of endosomal acid-
ification, can block the poly(I:C)-induced biological response in
monocyte-derived DCs (MoDCs) (de Bouteiller et al., 2005).
Therefore, we next investigated whether TLR3 was
involved in the LC response to poly(I:C). To this end, LCs
were incubated with bafilomycin before poly(I:C) activation
and analyzed for phenotype and survival. As shown in Figure
5b and c, the increase in both CD80 and CD86 expression on
poly(I:C)-treated LCs was completely blocked in the presence
of bafilomycin. Moreover, bafilomycin completely reversed
the effect of poly(I:C) on LC survival even at the highest
poly(I:C) concentration, 50 mg/ml (Figure 5a).
Poly(I:C)-treated LCs promote the differentiation of CD4þ
T cells producing IFN-c and IL-10
We then analyzed the ability of LCs to support allogeneic
naive CD4þ T-cell differentiation. As illustrated by the results
of three independent experiments (Figure 6a), LCs recovered
from a 2-day culture without any stimuli clearly skewed
alloreactive CD4þ T-cell differentiation toward a Th1
profile, as evidenced by the high level of secreted IFN-g
and lower level of IL-4 after one or two rounds of specific
stimulation. Poly(I:C) treatment of LCs resulted in lower IL-4
and far higher IFN-g production by the CD4þ T cells
(Figure 6a). Most interestingly, poly(I:C)-treated LCs pro-
moted IL-10 production by CD4þ T cells, especially after the
second round of LC stimulation. None of the cytokines were
detected in naive CD4þ T cells cultured in the absence of
LCs (Figure 6a).
The latter results were further analyzed by double
intracellular staining of activated T-cell suspensions at the
end of the second round of specific stimulation. As illustrated
in Figure 6b, the percentage of cells producing IFN-g was
higher with poly(I:C)-treated than with untreated LCs (from an
average of 17±3 to 33±3% in the three experiments),
whereas the percentage of IL-4-producing cells was com-
paratively very low under any condition. Interestingly, IL-10
originated from two distinct populations, one producing IL-10
exclusively and the other secreting both IFN-g and IL-10,
both being increased after poly(I:C)-treated LC stimulation.
Globally, the percentage of IL-10-producing cells increased
from 1.4±0.8 to 4.9±2.1% upon poly(I:C)-treated LC
stimulation in the three experiments. Note that negative
double staining with anti-langerin and anti-IFN-g mAbs
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Figure 1. Poly(I:C) strongly up-regulates co-stimulatory molecules on human epidermal LCs. Freshly isolated LCs were treated or not with poly(I:C) (10 mg
ml1), CpG (10 mg ml1), LPS (100 ng/ml), or CD40 ligationþ IFN-g for 2 days in serum-free medium. Double staining was performed using anti-langerin and the
indicated mAbs. (a) Data from a representative experiment showing flow cytometry profile of LCs treated or not with poly(I:C), CpG, or LPS. (b) Mean MFI ratio
of treated to untreated LCs: results are the mean±SD of five experiments carried out with different donors. Statistical significance was assessed using Student’s
t-test: *Po0.05; **Po0.01; ***Po0.001.
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eliminated LCs as a possible source of IL-10 following
allogeneic CD4þ T cell contact (not shown).
Addition of neutralizing anti-IL-12 p70, anti-IL-23 mAb does not
block the production of IFN-c by LC-stimulated CD4þ T cells
We then analyzed whether minute and undetectable amounts
of IL-12 p70 and/or IL-23 that may be boosted during LC-T
cell interaction sufficed to drive the LC-induced Th-1
development. Accordingly, LC-T cell co-cultures were
carried out in the presence of a blocking mAb that reacts
with the p40 subunit of IL-12 p70 and IL-23. As shown in
Figure 7, the antibody did not alter the amount of IFN-g
produced by LC-stimulated CD4þ T cells. In contrast, it
decreased IFN-g production consistently when added to
control MoDC/CD4þ T cell co-cultures. Thus, as opposed to
MoDCs, LC-induced IFN-g production by CD4þ T cells
occurs independent of IL-12 p70 and/or IL-23.
DISCUSSION
Several recent studies using murine models have discarded a
role for LCs in initiating T-cell responses to viral antigens
(Allan et al., 2003; Kissenpfennig and Malissen, 2006). The
results are much debated, however, as in these murine
models, epidermal cells might be destroyed as a result of
heavy infection. To investigate whether human LCs respond
functionally to viral antigens, we used here in vitro stimula-
tion with poly(I:C). This study shows that poly(I:C) enhances
LC survival and allostimulatory function and promotes LC-
induced Th1 response and concomitant development of IL-
10-producing CD4þ T cells that might limit an exacerbated
inflammatory immune response. To our knowledge, this is
previously unreported data.
The results confirm and extend our earlier study (Flacher
et al., 2006) by showing that poly(I:C) strongly enhances the
expression of the co-stimulatory molecules CD40, CD80, and
CD86 even at the lowest concentration (5 mg/ml). This
activated phenotype is associated with an increased capacity
of the cells to induce an allostimulatory T-cell response. In
contrast, LCs are unresponsive to CpG-ODN 2216 and LPS
from Escherichia coli, in accordance with the non-expression
of their respective receptors, TLR4 and TLR9 (Flacher et al.,
2006; van der Aar et al., 2007).
Poly(I:C) may be recognized by the endosomal TLR3 and
the recently described cytoplasmic helicase protein MDA-5
(Kato et al., 2006). MDA-5 is critical for type I IFN secretion
(Gitlin et al., 2006), but we never detected interferon a or b in
our assays (not shown and Flacher et al., 2006). Moreover,
our data using bafilomycin show that TLR3 is involved in
poly(I:C)-mediated LC phenotypic activation and survival.
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Figure 3. Poly(I:C) enhances human LC allostimulatory function. Freshly
isolated LCs were treated or not with poly(I:C) (10 mg ml1), CpG (10 mg ml1),
LPS (100 ng ml1), or CD40 ligationþ IFN-g for 48 hours. Cells were then
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Therefore, TLR3 seems to be the main functional receptor
implicated in the human LC response to poly(I:C).
Currently, there are very few data concerning the ability of
authentic epidermal LCs to polarize the CD4þ T-cell
response. Here, we showed that highly purified human
epidermal LCs skew alloreactive naive CD4þ T cells toward
a Th1 profile. This occurred in the absence of the bioactive
heterodimer IL-12 (p40/p35), which has long been consid-
ered the major inducer of Th1 differentiation (Trinchieri,
2003). Indeed, mature LC stimulated or not with poly(I:C)
secrete only low levels of the IL-12 p40 subunit, even after
further ligation with CD40L-transfected cells combined with
IFN-g. The failure of both authentic and in vitro-generated
human LCs to produce a detectable amount of IL-12 p70 even
in response to viral or bacterial stimuli has already been
reported (Ebner et al., 2001, 2007; Berthier-Vergnes et al.,
2005; Morelli et al., 2005; Flacher et al., 2006). According to
Morelli et al. (2005), IL-23 might play a critical role in the
Th1-biasing capabilities of human skin migratory DCs,
including LCs. However, the authors showed the expression
of IL-23 p19 transcripts, whereas no information is available
concerning IL-23 protein secretion. In our study, LCs did not
produce detectable levels of IL-23, even after stimulation by
poly(I:C) or CD40Lþ IFN-g. The lack of IL-23 could not be
related to the assay procedure, because, using the same
method and half as many cells, substantial amounts of IL-23
were found in supernatants of CD40L-activated MoDCs (not
shown). IL-10, known to inhibit bioactive IL-12 and IL-23
production by DCs, was undetectable in our assays (not
shown), as reported previously (Flacher et al., 2006). Finally,
addition of a blocking mAb that reacts with the p40 subunit of
IL-12 p70 and IL-23 during the LC-T cell co-culture did not
alter the amount of IFN-g produced by CD4þ T cells. Taken
together, the results strongly suggest that LC-induced IFN-g
production occurs independent of IL-12 p70 and IL-23
production. Keratinocytes express TLR3 mRNA (Flacher
et al., 2006) and poly(I:C)-activated keratinocytes produce
type I IFN and IL-18 responsible for induction of the Th1
response (Lebre et al., 2003). IFN-a, IFN-b, and IL-18 were
never detected in poly(I:C)-treated LCs (not shown and
Flacher et al., 2006), showing that the influence of residual
keratinocytes is rather marginal. Additional experiments are
needed to identify LC-derived cytokines responsible for
directing Th1 differentiation. So far, it has not been examined
whether LCs are able to produce IL-27, another IL-12 family
member produced by MoDCs under LPS stimulation, which
also plays a key role in the early stages of Th1 responses
(Pflanz et al., 2002).
Enhancement of DC longevity is likely to have an impact
on the magnitude of T-cell priming. TLRs are able to trigger
the DC survival pathway by distinct complex mechanisms
(Hou and Van Parijs, 2004). Our finding that poly(I:C)
prolonged the survival of activated LCs by delaying sponta-
neous apoptosis is in line with the recent observation that
poly(I:C) may enhance DC survival only when type I IFN
signaling is absent (Hasan et al., 2007). Indeed, poly(I:C) was
unable to induce IFN-a or IFN-b secretion by epidermal LCs
(Flacher et al., 2006). If our results are physiologically
relevant, it is conceivable that poly(I:C), prolonging LC
survival, would increase the chance to mount a T-cell
response.
An interesting finding is that LC treatment with poly(I:C)
results not only in higher production of IFN-g but also in
higher IL-10 production by a subpopulation of CD4þ T cells.
Our attempts to identify the underlying mechanism of IL-10
production by LC-activated T cells require further investiga-
tion. Some new molecules of the B7 family have been shown
to negatively regulate T-cell immunity. In particular, high
levels of ICOSL on antigen-presenting cells have recently
been shown to drive the generation of IL-10-producing
regulatory T cells (Witsch et al., 2002; Ito et al., 2007). Little
is known, however, about ICOSL expression on LCs. We
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found that a few LCs weakly express ICOSL when freshly
isolated from epidermis, as illustrated in Figure S3
(2.3±1.2% CD1aþ /ICOSLþ cells, mean±SD of three
experiments). Interestingly, most of these cells strongly
express ICOSL after a 2-day culture in medium alone (Figure
S3, 70±15% in the three experiments). However, ICOSL up-
regulation was prevented upon LC treatment with poly(I:C)
(Figure S3, 10±6% stained LCs in the three experiments).
This makes it unlikely that the molecule alone was
responsible for the increased IL-10 production by the T cells
upon stimulation with poly(I:C)-treated LCs. Experiments are
currently under way to clarify whether other molecules of the
B7 family might be involved in this process.
It is tempting to speculate that IL-10 production by
poly(I:C)-treated LC T cells, especially upon stimulation,
might regulate an inappropriate inflammatory response to
virus. Indeed, studies in mice showed that TLR ligands,
including poly(I:C), can simultaneously function as adjuvants
in the adaptative T-cell response and suppressors via IL-10
production by CD4 T cells. Thus, poly(I:C) and LPS promote
CD8þ T cell priming in vivo but simultaneously induce
IL-10-producing CD4þ T cells that suppress the CD8þ T-cell
response (den Haan et al., 2007). Moreover, in many chronic
infectious diseases in humans and experimental animals,
functional effector Th1 cells have been shown to secrete
IL-10 (for review: Trinchieri, 2007). Those cells, distinct from
natural Foxp3þ regulatory T cells and other subsets of
induced regulatory T cells, may be involved in limiting the
damage caused by exaggerated inflammation (Jankovic et al.,
2007).
Interestingly, a recent study analyzed the impact of TLR3
activation on experimental asthma in mice (Sel et al., 2007).
Administration of poly(I:C) can prevent the allergic sensitiza-
tion as well as already established allergic inflammation.
Although the role of epithelial DCs in this process has
not been addressed directly, it is noteworthy that the
protective effect of poly(I:C) was based on both increased
Th1 response and increased IL-10 production, as observed in
our in vitro assays. Whether poly(I:C) can be efficient in the
modulation of inflammatory human skin diseases remains to
be investigated.
In conclusion, our data provide new insights into a
decisive role for human epidermal LCs in defense against
viral infection, mimicked by poly(I:C). If the present in vitro
findings have a physiological relevance, they suggest that LCs
might be efficient inducers of Th1-biased immune responses
although concomitant LC-induced IL-10 production by the T
cells might limit, in a second step, the inflammatory response.
MATERIALS AND METHODS
Culture medium and reagents
Culture medium was X-VIVO-15 supplemented with 1% gentamycin
(Sigma, St Louis, MO) and 200Uml1 recombinant human GM-CSF
(specific activity: 2 106 U mg1, a generous gift from Schering-
Plough Research Institute, Kenilworth, NJ), called complete medium
in this paper. Chemically synthesized dsRNA, poly(I:C), CpG-ODN
2216, and LPS from E. coli were obtained from InvivoGen (San
Diego, CA).
Human epidermal LC purification
LCs were highly purified using a slightly modified, previously
described technique (Berthier-Vergnes et al., 2005). Briefly, epider-
mal cell suspensions were obtained by trypsinization of human
abdominal skin obtained by plastic surgery (0.05% trypsin, Difco
Laboratories, Detroit, MI, overnight, 4 1C). LCs were enriched and
purified by three successive density gradient centrifugations: the first
was performed on Lymphoprep (density 1.077, Flobio SA, Courbe-
voie, France), whereas the other two were done on Nycoprep
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Figure 5. Bafilomycin inhibits poly(I:C)-mediated LC survival and
phenotypic activation. LCs were treated or not with 50 nM bafilomycin before
poly(I:C) activation and analyzed after 2 days for survival (a) and phenotype
(b and c). (a) LCs were double stained with Annexin V-FITC and propidium
iodide. Numbers represent the percentage of cells in each quadrant. (b) For
phenotype analysis, viable cells (Annexin V and PI cells) were first gated
according to FSC and SSC parameters, and analysis was carried out in gate R1.
(c) Histograms represent the mean fluorescence intensity for CD80 and CD86
on viable LCs after treatment, or not, with poly(I:C) in the presence (gray) or
absence (white) of bafilomycin. The results are representative of two
independent experiments.
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(density 1.077), diluted with distilled water (4.5ml/0.5ml). LCs were
recovered at the interface and then washed and enumerated. Using
this procedure, the number of viable LCs recovered after the three
steps of purification was about 1% of the total epidermal cells
obtained after trypsin treatment (0.96þ 0.37%, mean of 15 experi-
ments). Given that the percentage of LCs in the total epidermal cell
suspension was routinely about 2–4%, as assessed by microscopic
examination, this implies that approximately one-third of LCs could
be retrieved in the purified population. This population routinely
consists of more than 90% viable immature LCs, as assessed by flow
cytometry analysis using anti-CD1a-FITC (NA1/34) from Dako
(Glostrup, Denmark), anti-Langerin-PE (DCGM4) from Immunotech
(France), and anti-CCR6-FITC (53103.111) from R&D Systems
Europe Ltd (Abington, UK).
LC activation
Highly purified LCs were suspended in complete medium and
cultured at 106 cells ml1 in 24-well culture plates (Falcon, Becton-
Dickinson, Lincoln Park, NJ) in the presence or absence of poly(I:C),
CpG-ODN 2216, or LPS at various concentrations. For CD40
triggering, 106 LCs were seeded with IFN-g (1,000U ml1) and 105
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Figure 6. Poly(I:C) promotes LC-induced Th1 differentiation with concomitant IL-10 production. Allogeneic naive CD4þ T cells were stimulated one or two
times with LCs treated or not with poly(I:C) at 25mg ml1. At the end of each round of stimulation, PMA and ionomycin were added. (a) After 24 hours,
supernatants were collected and analyzed for Th1/Th2 cytokines. The cytokine concentration is expressed in pg ml1. The results are from three independent
experiments carried out with different donors. (b) After the second round of LC stimulation, brefeldin A was added at the same time as PMA and ionomycin and
intra-cellular staining was performed after 5 hours. The percentage of positive cells is indicated in the quadrants. The results are from Exp 1 and representative of
the other two experiments.
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Figure 7. LC-induced IFN-c production by CD4þ T cells is independent of
bioactive IL-12 and IL-23. Allogeneic naive CD4þ T cells were co-cultured
with LCs or MoDCs pre-treated or not with poly(I:C) at 25mg ml1, in the
presence, or not, of anti-IL-12 and IL-23 neutralizing mAb (anti-p40). After 6
days, PMA and ionomycin were added, and cell supernatants were collected
24hours later. IFN-g production was quantified using the human Th1/Th2
cytokine kit. The results are from experiments carried out with two different
donors.
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irradiated fibroblastic L cells transfected with the human CD40
ligand (CD40L, kindly provided by Schering Plough Laboratories,
Dardilly, France). After 2 days, the cell supernatants were harvested
and stored at 80 1C until cytokine measurement. LCs were counted
in the presence of trypan blue to assess their viability and analyzed
for phenotype and apoptosis. After extensive washing, LCs were used
either directly for naive CD4þ T-cell polarization or frozen until
needed for CD4þ T cell re-stimulation.
In some experiments, LCs were incubated for 45minutes with
bafilomycin (50 nM) before poly(I:C) treatment and were analyzed 2
days later for phenotype and apoptosis.
Phenotypic analysis
LCs were double stained with anti-Langerin-PE and a panel of FITC-
labeled mAbs, either after purification or after a 2-day culture in the
presence or absence of poly(I:C), LPS, CpG-ODN 2216, or
CD40Lþ IFN-g. FITC- and PE-conjugated mAb were incubated at
the same time for 30minutes at 4 1C, and controls were carried out
with irrelevant isotype-matched Igs. The following FITC-labeled
mAbs were used: anti-HLA-DR (B8.12.2), anti-CD54 (84H10), anti-
CD80 (MAB 104), anti-CD83 (HB15A), and anti-CD40 (mAb89), all
from Immunotech (Marseille, France); anti-CD86 (2331FUN-1) from
BD Pharmingen (San Diego, CA); and anti-CD1a (NA1/34) from
Dako (Glostrup, Denmark). Analysis of fluorescence staining was
performed with a FACScan flow cytometer (Becton Dickinson, Le
Pont de Claix, France) using the CELLQuest software. The LC
population was gated electronically according to cell surface
langerin expression. The results for a given antigen are expressed
as the following ratio: MFI in the presence of the TLR ligand/MFI in
the absence of TLR ligand.
Apoptosis
LCs—both those exposed to poly(I:C) and those not exposed—were
evaluated for apoptosis at day 2, 3, or 4 of culture by double staining
with PI and FITC-conjugated annexin V according to the manufac-
turer’s instructions (Annexin V-FITC kit, Immunotech).
T-cell purification
Allogeneic T cells were purified from peripheral blood mononuclear
cells by rosetting with sheep red blood cells as described previously
(Kaplan and Clark, 1974). Naive CD4þ T cells were obtained by
negative selection using the naive CD4þ T-cell isolation kit
(Miltenyi Biotec, Bergisch-Gladbach, Germany). Alternatively, naive
CD4þ T cells were purified from umbilical cord blood using CD4
microbeads (Miltenyi Biotec) and used without altering the results.
Cells were routinely 96–98% pure CD4þ and contained 0.01–0.7%
CD4þ /CD45ROþ memory T cells, as assessed by flow cytometry.
T-cell proliferation
Mixed LC–lymphocyte reactions were carried out in 96-well round-
bottomed microtiter plates by adding bulk allogeneic T cells (105
cells) to varying numbers of viable LCs. Controls with LCs or T cells
alone were included in each experiment. Culture medium was
RPMI-1640 (Gibco Laboratories, Grand Island, NY) supplemented
with 10% human AB serum. Triplicate cultures were maintained for
6 days at 37 1C in a 5% CO2 humidified atmosphere. T-cell
proliferation was measured by pulsing the cells with 1 mCi of
[3H]methylthymidine (5 Ci/mmol; Amersham Pharmacia Biotech,
Les Ulis, France) for the final 18 hours of culture. Cells were then
harvested, and incorporated thymidine was quantified in a direct b-
counter (Matrix 96; Packard, Downers Grove, IL). The results were
expressed as the mean counts per minute±SD of triplicate cultures.
Polarization of naive CD4þ T cells
LCs (105 cells), treated or not with poly(I:C) at 25 mg ml1, were
added to allogeneic naive CD4þ T cells (106 cells) in RPMI-1640
medium supplemented with 10% human AB serum. After 6 days,
rhIL-2 (50U/ml1) was added, and the cells were expanded for
another 7 days. Thirteen days after initiation of the culture, T cells
were collected, washed, and stimulated with phorbol myristate
acetate (PMA) (10 ng ml1; Sigma) and ionomycin (1 mg ml1;
Sigma-Aldrich). Supernatants were collected after 18 hours and
stored at 80 1C until Th1/Th2 cytokines were measured. Alterna-
tively, after 13 days, T cells were subjected to a second round of
specific stimulation, that is, they were restimulated with the same
LCs (105 cells) used in the primary culture, treated or not with
poly(I:C), and kept frozen. After 3 days, rhIL-2 (50U ml1) was
added. One week after initiation of the second stimulation, T cells
were collected, washed, and stimulated with PMA and ionomycin as
described earlier. Supernatants were collected after 18 hours and
stored at 80 1C until Th1/Th2 cytokines were measured.
Intracellular cytokine staining was carried out at the end of the
second round of stimulation. To this end, brefeldin A (10mM, Sigma,
St Louis, MO) was added simultaneously with PMA and ionomycin
and after 5 hours, cells were harvested and stained with anti-IFN-g-
Alexa Fluor 488 (AF), anti-IL-4-PE, or anti-IL-10-PE (BD Pharmingen)
after fixation and permeabilization with Intrastain Fix/Perm (Dako).
A mixture of PE- and AF-conjugated irrelevant isotype-matched
mAbs were used as controls. In some experiments, cells were
surface double-stained with CD4 and langerin (BD Pharmingen, San
Diego, CA).
Neutralization of IL-12/IL-23 bioactivity
In some experiments, primary LC-T cell co-cultures were carried out
in the presence of a neutralizing anti-human IL-12/IL-23 mAb that
reacts with the p40 subunit (C8.6 clone, eBiosciences, 10 mg ml1).
As control, CD4þ T cells were stimulated with MoDCs obtained
after a 6-day monocyte culture in the presence of GM-CSF and IL-4,
as described previously (Pe´guet-Navarro et al., 2003). After the 6-
day co-culture, cells were stimulated with PMA and ionomycin as
described earlier. Supernatants were collected after 18 hours and
stored at 80 1C until Th1/Th2 cytokines were measured.
Cytokine assays
The supernatants of LCs, treated or not with poly(I:C), CpG, LPS, or
CD40Lþ IFN-g, were analyzed for levels of IL-15 (sensitivity: 2 pg
ml1), IL-18 (sensitivity: 12 pg/ml), and IL-23 (sensitivity: 20 pg ml1)
by conventional ELISA (R&D Systems Europe Ltd). IL-12 p40, IL-12
p70, IL-1b, IL-10, CXCL-10 (IP-10), TNF-a, and IL-6 were measured
using the BD CBA human inflammation kit (BD Biosciences,
Mountain View, CA) and the LUMINEX Beadlyte cytokine detection
system (Upstate Biotechnology, Lake Placid, NY), according to the
manufacturers’ protocols.
The cytokines present in the supernatants of LC/CD4þ T cell co-
cultures were measured using the BD CBA Human Th1/Th2 cytokine kit
according to the manufacturer’s recommendations (BD Biosciences).
1970 Journal of Investigative Dermatology (2009), Volume 129
L Furio et al.
Poly(I:C)-Treated Langerhans Cells
Statistical analysis
The results were analyzed for statistical significance using Student’s
t-test. Only P-values o0.05 were considered statistically significant
(*Po0.05, **Po0.01, ***Po0.001).
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SUPPLEMENTARY MATERIAL
Figure S1. Poly(I:C) strongly up-regulates co-stimulatory molecules on human
epidermal LCs.
Figure S2. Poly(I:C) enhances human LC allostimulatory function.
Figure S3. ICOS ligand expression on human LCs.
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